Altogen Labs

08/01/2025

Cancer research relies on precise, reproducible preclinical models to translate scientific discoveries into effective therapies. A newly published review article, “In Vitro Antiviral Assays: A Review of Laboratory Methods” (Analytical and Diagnostic Techniques, 2024), underscores the role of Altogen Labs’ preclinical services in this process https://www.liebertpub.com/doi/full/10.1089/adt.2024.075?utm. Highlighted services include our HL‑60 Xenograft Model, designed for robust leukemia efficacy testing, and our BHK‑21 Transfection Reagent, optimized for high-efficiency gene delivery in functional assays.
The HL‑60 model enables quantitative evaluation of tumor response and pharmacodynamics in leukemia research, while the BHK‑21 reagent empowers scientists to manipulate gene expression and validate oncogenic pathways in vitro. These combined platforms offer a powerful toolkit for cancer drug development. Altogen Labs’ support enables translational study designs that enhance scientific rigor and speed up therapeutic discovery.
To learn more about how Altogen’s services support cancer research innovation, see our xenograft and transfection reagent pages linked below.
https://altogenlabs.com/xenograft-models/

Viral diseases remain a significant challenge for global health with rising fatalities each year. In vitro assays are crucial techniques that have been utilized by researchers in the quest to develop antiviral therapies. These assays mimic the internal conditions of a living system and make it possi...

07/31/2025

Cancer remains one of the most pressing global health challenges, driving researchers to innovate better and more targeted therapies. A recent breakthrough comes from a study published in Annals of Translational Medicine, which describes the development of a site-specific antibody–drug conjugate (ADC) that targets CD33, a well-established biomarker in acute myeloid leukemia (AML).

The publication titled “Design and development of anti-CD33 antibody–drug conjugate for targeted acute myeloid leukemia therapy” details how this ADC achieved potent and selective cytotoxicity in leukemic cells. A key component of this success was the in vivo efficacy data generated by Altogen Labs. By utilizing Altogen’s advanced preclinical xenograft testing services, the research team was able to demonstrate meaningful tumor inhibition in AML models.

This citation exemplifies how Altogen Labs plays a critical role in oncology research by delivering high-quality preclinical study support. The company’s xenograft efficacy and toxicology services enable biotech innovators to evaluate therapeutic efficacy with precision and confidence. Such studies form the foundation of data packages needed for regulatory filings and clinical development.

Altogen Labs is honored to have supported this important research effort, furthering the development of effective and safer therapies for hematologic malignancies. Learn more about the study here:https://cdn.amegroups.cn/journals/amepc/files/journals/16/articles/116683/public/116683-PB1-9412-R1.pdf
Explore our preclinical services: https://altogenlabs.com/xenograft-models/

07/30/2025

Cancer remains one of the most complex and urgent health challenges of our time. At Altogen Labs, we are proud to contribute to innovative approaches that push the boundaries of targeted cancer therapy. The April 2021 OncoLife Therapeutics slide deck features our role in supporting preclinical studies of antisense oligonucleotide (A*O) therapeutics targeting hepatocellular carcinoma (HCC), a devastating form of liver cancer.
The research focuses on identifying small genetic differences between cancer and healthy stem cells—a strategy that promises greater therapeutic precision and less systemic toxicity. To support this breakthrough approach, Altogen Labs conducted efficacy studies in HepG2 liver cancer models, evaluating several A*O candidates over a six-week treatment course. These studies generated critical data on tumor growth inhibition, therapeutic response, and compound tolerability. Our In Vivo Safety Toxicology services further ensured that emerging candidates demonstrated promising safety profiles prior to clinical advancement.
This collaboration reflects the broader importance of preclinical oncology platforms that can predict translational outcomes and optimize therapeutic strategy. Altogen Labs remains a committed partner in oncology drug development, offering validated xenograft models and full-spectrum biology CRO services.
To explore our services, visit: https://altogenlabs.com/xenograft-models/

07/29/2025

Can compounds from green tea contribute to cancer treatment? A recent academic study titled “Colorectal Cancer and Green Tea Extract: Evaluation of Treatment Efficacy Using In Vitro and In Vivo Imaging Methods” explores this idea by testing the impact of polyphenol-rich extracts on colorectal cancer models.

The study used IC50 testing to evaluate the cytotoxicity of the compound across tumor cell lines, followed by animal imaging to assess therapeutic effects in vivo. Altogen Labs is cited for its IC50 testing services—an essential pharmacological tool for dose-response profiling of investigational compounds.

Altogen Labs supports oncology research by offering both in vitro and in vivo preclinical services, including validated colorectal xenograft models and quantitative toxicology testing.

To learn more about our services, visit:

Altogen Labs in-house validated xenograft models (CDX and PDX; mouse and rat models): Tumor type: Altogen Labs in-house validated xenograft models: Brain LN229 , SF268 , SF295 , A172 , SF539 , SK-N-AS , SNB-19 , SNB-75 , U-251 MG , U87 MG , U118 , U87-Luc Breast Cancer 4T1 , BT474 , CAL51 , HS578T ,...

07/28/2025

How can we make mitochondrial uncouplers safe for obesity treatment? A new study published in Scientific Reports offers a novel solution: conjugating uncoupler compounds with hydrophobic chains to target adipose tissue selectively.

The research introduces NMY1009, a modified uncoupler that accumulates in white adipose tissue while sparing other organs. In vivo toxicity testing was performed by Altogen Labs, which confirmed that daily dosing up to 100 mg/kg for 7 days was well-tolerated in mice.

Altogen Labs is proud to support early-stage therapeutic innovation with high-quality in vivo toxicology and safety pharmacology services. This citation reflects our role as a trusted preclinical partner for academic and industry clients alike.

Learn more about our preclinical services:
https://altogenlabs.com/xenograft-models/

07/27/2025

We’re proud to announce that Altogen Labs is featured in the Oncolife Therapeutics investor update for their liver cancer program. The April 2021 slide deck outlines a preclinical study using our validated HepG2 xenograft model to test a novel antisense oligonucleotide (A*O) therapy for hepatocellular carcinoma.

Altogen Labs will perform the full suite of in vivo studies, including 45-day subcutaneous A*O dosing, tumor efficacy monitoring, and GLP-compliant toxicology assessments in HCC-bearing mice. This includes both unconjugated and GalNAc-conjugated A*O variants designed to modulate gene expression selectively in liver tissue.

We’re honored to serve as a biology CRO partner for companies advancing oligonucleotide therapeutics and gene modulation technologies.

Explore our xenograft model services and capabilities in oligo-based preclinical research:

Altogen Labs in-house validated xenograft models (CDX and PDX; mouse and rat models): Tumor type: Altogen Labs in-house validated xenograft models: Brain LN229 , SF268 , SF295 , A172 , SF539 , SK-N-AS , SNB-19 , SNB-75 , U-251 MG , U87 MG , U118 , U87-Luc Breast Cancer 4T1 , BT474 , CAL51 , HS578T ,...

07/26/2025

Xenotransplantation has emerged as a vital research strategy in cancer and regenerative medicine, and we’re proud to be cited in a review article titled “Xenotransplantation – A Review,” published in the World Journal of Pharmaceutical Research.

The article discusses the application of xenografts—transplants between species—as a research method, including the transplantation of human tumor cells into immunocompromised mice. This approach plays a crucial role in oncology drug development, allowing researchers to assess tumor growth, treatment response, and molecular mechanisms in vivo.

Altogen Labs was cited for providing xenograft animal models in preclinical research. With over 100 validated tumor xenograft systems, Altogen Labs enables pharmaceutical companies and academic researchers to accelerate drug discovery and translational studies.

To explore our xenograft services, visit:

Altogen Labs in-house validated xenograft models (CDX and PDX; mouse and rat models): Tumor type: Altogen Labs in-house validated xenograft models: Brain LN229 , SF268 , SF295 , A172 , SF539 , SK-N-AS , SNB-19 , SNB-75 , U-251 MG , U87 MG , U118 , U87-Luc Breast Cancer 4T1 , BT474 , CAL51 , HS578T ,...

07/25/2025

Can natural compounds like thymoquinone regulate cancer-driving microRNAs? A 2023 study published in Genes explores this possibility by examining miRNA expression profiles in prostate and colon cancer cells.

The article, titled “Thymoquinone Potentially Modulates the Expression of Key Onco- and Tumor Suppressor miRNAs in Prostate and Colon Cancer Cell Lines,” used the HCT-15 colon cancer cell line to demonstrate that thymoquinone downregulates oncomiRs (e.g., miR-21, miR-155) and upregulates tumor suppressors like miR-34a.

Altogen Labs was cited for its HCT-15 xenograft model, used widely in preclinical colon cancer studies. Our xenograft models allow researchers to investigate tumor biology, therapeutic efficacy, and mechanistic signaling pathways in vivo.

To learn more about our colon cancer xenograft services, visit:
https://altogenlabs.com/xenograft-models/

07/24/2025

Altogen Labs is honored to have contributed to a published study in Histology and Histopathology titled “Pathogenicity assessment of wild-type and mouse-adapted influenza A(H1N1)pdm09 viruses in comparison with highly pathogenic influenza A(H5N1) virus.”

The study evaluated the systemic effects of three different influenza virus strains in mice, comparing clinical severity, histopathological damage, and viral replication. The mouse-adapted A(H1N1)pdm09 strain demonstrated virulence comparable to the highly pathogenic A(H5N1) strain, revealing important implications for influenza virus evolution and cross-species transmission.

Altogen Labs was formally acknowledged for its role in study consultation and modeling expertise. We are proud to support translational virology through preclinical model development, histopathological analysis, and infectious disease research services.

Learn more about our validated modeling services at:
https://altogenlabs.com/xenograft-models/

07/23/2025

How do mechanical properties of glioblastoma cells affect tumor growth and therapy resistance? A 2025 Scientific Reports study titled “Exploring the heterogeneity in glioblastoma cellular mechanics using in-vitro assays and atomic force microscopy” addresses this emerging question using advanced biophysical tools.

The authors applied atomic force microscopy to characterize differences in stiffness and deformability across glioblastoma subtypes, using U87 as a representative model. Their findings highlight that mechanical phenotyping may be a useful tool for understanding glioblastoma heterogeneity and guiding treatment decisions.

Altogen Labs was cited for its U87 Xenograft Model, which has long served as a foundational platform for glioblastoma drug development and preclinical evaluation.

To learn more about our U87 xenograft model and other brain tumor services, visit:
https://altogenlabs.com/xenograft-models/

07/22/2025

Altogen Labs is pleased to announce that its SKOV3 xenograft model was cited in a study published in Investigational New Drugs, titled “Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.”

This preclinical investigation tested the efficacy of alofanib (RPT835) against ovarian tumors, using Altogen Labs’ in vivo SKOV3 xenograft model to measure tumor growth, proliferation, and angiogenesis. The study showed dose-dependent tumor suppression, with up to 80% inhibition achieved through intravenous administration, and further enhanced efficacy in combination with paclitaxel and carboplatin.

Altogen Labs offers over 100 validated xenograft models for drug testing in solid tumor indications. Our SKOV3 model is widely used for evaluating novel anti-angiogenic and receptor-targeted therapies in ovarian cancer.

To learn more about our xenograft tumor services, visit:
https://altogenlabs.com/xenograft-models/

07/21/2025

Cell lines are the foundation of cancer research—but without consistent documentation and authentication, they can compromise data integrity and reproducibility. A new article published in NPJ Precision Oncology, titled “Research reporting guidelines for cell lines: more than just a recommendation,” proposes urgently needed reforms to how cell line experiments are reported in biomedical research.

Altogen Labs is cited in this publication for its SMMC-7721 liver cancer xenograft model, which was highlighted as an example of a well-documented and standardized in vivo model. The SMMC-7721 model is used in numerous preclinical oncology programs and supports the development of therapies targeting hepatocellular carcinoma.

We’re proud to contribute to global efforts in reproducibility, transparency, and the responsible use of biological models in oncology.

Learn more about our SMMC-7721 and other validated xenograft tumor models here:

Altogen Labs in-house validated xenograft models (CDX and PDX; mouse and rat models): Tumor type: Altogen Labs in-house validated xenograft models: Brain LN229 , SF268 , SF295 , A172 , SF539 , SK-N-AS , SNB-19 , SNB-75 , U-251 MG , U87 MG , U118 , U87-Luc Breast Cancer 4T1 , BT474 , CAL51 , HS578T ,...